Thu, Oct 23, 2014, 1:21 AM EDT - U.S. Markets open in 8 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

Aethlon Medical, Inc. Message Board

ftd_1999 3 posts  |  Last Activity: Sep 8, 2014 10:25 PM Member since: Jul 17, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ftd_1999 ftd_1999 Sep 8, 2014 10:25 PM Flag

    It is not an investment conference and likely will not even be broadcast. You can expect year 4 of the DARPA award any day now. After completing milestone M5 90% clearance for at least 3 identified targets, Aethlon will almost certainly be a part of the final solution.

  • Reply to

    DARPA and AEMD

    by floydtrainer Aug 15, 2014 2:51 PM
    ftd_1999 ftd_1999 Aug 15, 2014 10:10 PM Flag

    I don't think you have a clue what you are talking about. What exactly do you think the many other awardees are contributing? Did you read the DARPA solicitation DARPA-BAA-11-30? All the awardees have their own solution, not just AEMD and CTSO. For example Wyss's 'splean on a chip'. There is a teaming website (http://teaming.sysplan.com/BAA-11-30/abstracts.html?3.+PROPOSERS+DAY+POSTER+ABSTRACTS) available where you can see the many 'initial' awards. There is definitely some serious competition out there for this contract.

    In regard to your comments about the reduced scope, it was -$858K and related to some tasks Aethlon tried to sweep in. We do it all the time in the defense industry in which I work. To draw a conclusion that Aethlon has been eliminated from this is obsurd.

    You are obviously biased and don't know anything about Aethlon. Take a look at their 10K which lindicates the following:

    Milestone M5 – Target capture 90% in 24 hours for at least three targets in blood or blood components. The milestone payment was $208,781. Management considers this milestone to be substantive as it was not dependent on the passage of time nor was it based solely on another party's efforts. We demonstrated that we were able to capture 90% in 24 hours for at least three of the agreed targets in blood or blood components. The report was accepted by the contracting officer's representative and the invoice was submitted thereafter.

    Aethlon has met this task (Technical task 3 of 6 per solicitation) ahead of schedule. Also as evidenced in the recent 10-Q, Aethlon continues to bill Battelle for advanced work on integrating their device into the final solution. Though there can be no assurances, this is a pretty good indication that Aethlon will be there in the end. I don't know (or care) where CSTO is with their approach. I am only posting here because your misguided post showed up on the AEMD I-hub board.

  • Reply to

    Insiders Acquire more share 06 June at .19

    by investa_gator1 Aug 1, 2014 11:35 AM
    ftd_1999 ftd_1999 Aug 3, 2014 11:06 PM Flag

    Don't read too much into it. Aethlon only had $200K+ in cash at fiscal year end (not to be confused with Exosome Sciences cash balance). Insiders have been funding Aethlon for a long long time.